Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2025-02-23 Director's Dealing
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Initial Director's Interest Notice 3 pages 296.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares and warrants, and provides information about the director's appointment date. The content focuses on the disclosure of personal shareholdings and interests of a company director, which aligns with insider trading or director dealings disclosures. The document length is short (2896 characters) and is a formal notification of director's share interests rather than a financial report or announcement of a meeting or vote. Therefore, the appropriate classification is Director's Dealing (DIRS).
2025-02-23 English
6-K
Regulatory Filings
2025-02-14 English
Ryoncil Highlighted at Tandem Transplantation Meetings 3 pages 288.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the FDA approval and market launch of Mesoblast's product Ryoncil. It highlights the product's approval, upcoming presentations at a medical conference, and company background information. There are no financial statements, detailed financial performance data, or regulatory filings such as 10-K or interim reports. The document is primarily an announcement of a product approval and market launch, not a financial or regulatory report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content as a corporate announcement about product approval and market launch, it best fits under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-02-13 English
Regulatory Filings 2025
Regulatory Filings
2025-02-13 English
PROSPECTUS
Regulatory Filings
2025-02-12 English
Regulatory Filings 2025
Regulatory Filings
2025-02-10 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.